Barclays PLC Finch Therapeutics Group, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$1.91 - $5.11 $2,349 - $6,285
-1,230 Reduced 92.07%
106 $0
Q1 2022

May 16, 2022
BUY
$5.02 - $10.47 $6,706 - $13,987
1,336 New
1,336 $7,000

About Finch Therapeutics Group, Inc.

FNCH Quotes by TradingView
  • Ticker FNCH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,688,400
  • Market Cap $525M
  • Description
  • Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...
More about FNCH
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email